Vyvanse correction
Executive Summary
Shire's Vyvanse (lisdexamfetamine) is the first stimulant for attention deficit/hyperactivity disorder to include results of abuse liability studies in labeling, but like all stimulant medications, has the potential for abuse and is classified as a Schedule II Controlled Substance. As a result, Shire is not promoting Vyvanse as having a lower potential for abuse versus Adderall XR as reported in "The Pink Sheet," Jan. 19
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.